政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/34305
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 113451/144438 (79%)
Visitors : 51261821      Online Users : 865
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/34305


    Title: 生技醫藥公司之投資評估研究－生物倫理與社會責任之價值
    Authors: 陳宜超
    Chen,Yi-Chau
    Contributors: 劉江彬
    Liu,Paul C. B.
    陳宜超
    Chen,Yi-Chau
    Keywords: 生技醫藥
    生技藥品
    檢體
    人體臨床試驗
    投資評估
    生物倫理
    社會責任
    生技品牌
    Biomedicine
    Biopharmaceutical
    Specimen
    Human clinical trials
    Investment evaluation
    Bioethic
    Social responsibilities
    Biobrands
    Date: 2004
    Issue Date: 2009-09-18 09:19:48 (UTC+8)
    Abstract: 繼人體基因圖譜於2000年解碼後，基因解讀及研究初期均在競爭解讀基因序列(Gene sequences)，然而了解基因序列是一件事，如何從序列中來了解基因功能所賦予之生理生化意義，比如每段基因所產生之蛋白質產物、及蛋白質與細胞之間的相互關係等資訊，進而應用於藥物標的之尋找，才是未來生物醫學發展之主要方向。同理，藉由基因功能學(Functional Genomics)領域來研究新發現之基因的功能、基因表現、與蛋白質產物，進而辨識有用的藥物標的(Drug target)及尋找新的疾病治療方法，才是基因解讀後最主要之生技醫療市場。全球生物科技之應用中以醫療用的生技產品所帶來的產值最為可觀，佔總體生技產業約七成以上之產值，其中又以重組蛋白藥品、單株抗體、疫苗及檢驗試劑之研發為主要重心，其中行政院更在“加強生物技術產業推動方案”裡，特別將蛋白藥物、抗癌藥物開發及檢驗試劑等領域列為重點推動項目，國內外許多生物科技公司研發專長及主軸亦座落於全球最熱門的生技製藥發展脈絡上。目前由於許多癌症、代謝失常疾病、遺傳性疾病及自體免疫疾病等，臨床之治療藥物仍舊是付之闕如或是供不應求，其中特別是各種癌症以及自體免疫疾病，如類風濕性關節炎、多發性硬化症、牛皮癬及過敏等，都是生技醫藥開發非常重要之疾病研究領域。現今臨床上所常用的藥物，普遍有特異性不佳、副作用大的缺點，因此國內外許多生物科技公司正戮力於針對上述疾病類別找尋合適之生技藥物或是小分子藥物，已達到標的治療(Target therapy)為目的；然而在生技醫藥公司草創初期，大都以技術掛帥，且由於藥品開發時間冗長，因此鮮少有生技醫藥公司能於設立初期10年內有產品上市，因此導致初期營運風險居高不下，令投資者裹足不前，所以如何評估具有成長潛力之生技醫藥公司頗為困難，因此本論文擬從生技藥品著手，除了傳統從技術面、產品面、市場面、競爭者、人力資源、策略經營等構面著手分析成長中之生技醫藥公司外，由於生技醫藥產業之特殊屬性，所以更特別注重產業成長時針對生物倫理面的考量，以做為生技醫藥公司具成長潛力之指標之一。希望透過多元的評估分析，能夠歸納出生技醫藥公司的成功要素，並藉此分析能夠有系統的篩選出具成長性、具社會責任之生技醫藥公司，才能擘畫生技醫藥公司維持長期競爭力、獲得永續發展的遠景，並藉此做為投資者長期投資評估之參考依據。
    The completion of the human genome project is regarded as a turning point in biotechnology and medicine. This project is expected to produce sequence of DNA representing the functional blueprint and evolutionary history of the human species. As we entered the postgenomic era, what we faced is the explosion of new information, which is leading to dramatic changes in the way we are able to study and manipulation of life. At the first few years, many groups were competing in sequence decoding. However, the findings of the functions of genes and the interactions of different gene products are the main issues helping us exploit the new biotechnology markets. Through the research of functional genomics to explore the function, expression, and protein products of novel genes is helpful in identifying new drug targets and developing therapeutic strategies in treating various diseases. This is what we emphasized in biotech market after entering the postgenomic era. The most valuable branch of biotechnology industry is the medical products in global biotechnology market. The medical products take up to 70% of total sales in biotechnology markets. Among the medical biotechnology field, recombinant protein drugs, monoclonal antibodies, vaccines, and detection kits have been focused in pharmaceutical R&D investment. Executive yuan of the Republic of China decided to emphasized in protein drugs, anti-cancer drug development and detection kits in their “ The promotion plan of improving biotechnology industry”.

    Currently, the drugs against cancers, metabolic diseases, inherited diseases, and autoimmune diseases are still unavailable. Especially the drugs for various cancers, and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, and allergy are under intensive investment in global biotechnology industry. This is because the drugs used today have the deficiencies including low specificity and adverse side effects. Thus, target therapy using monoclonal antibodies and small molecular drugs are the goals for worldwide biotech companies. However, the development in research has been considered as the most important thing in the starting stage of newly founded biotech companies and the long time needed for putting a new drug to market make very few biotech companies have salable products. Thus, the newly biotechnology company has been considered has high risk in the beginning stage. This makes investors to hesitate in putting their money in this field. To evaluate the potential of a new biotechnology companies is difficult since the complex of this industry. This study will try evaluating a newly founded biotechnology company not only through technology, product, market, competitors, human resources, strategies, but also from the consideration in bioethics. Hopefully, through the evaluation of multiple markers, we can conclude the essential factors for a successful company and screen out the company with high growing potential via this study. Finally, this study might serve as a reference for investors in evaluating a promising company for long-term investment.
    Reference: 中文資料：
    1. 王維敏 等 (民 91年)。生技投資的億萬商機。時報出版社。
    2. 朱兆文 (民 92年)。生技藥品及其學名藥之發展趨勢。生物技術開發中心。
    3. 江晃榮 (民 94年)。2004年生物技術產業發展動向與研發趨勢(二) 275。科技報導，第20版。
    4. 江晃榮 (民 94年)。2004年生物技術產業發展動向與研發趨勢(三) 280。科技報導，第14版。
    5. 吉娜. 柯拉塔 (民 87年)。基因複製：從複製羊桃莉看人類未來。遠流出版社。
    6. 何懷宏 (民 91年)。倫理學是什麼。揚智文化事業股份有限公司。
    7. 林子儀、蔡明誠 (民 92年)。基因技術挑戰與法律回應。學林文化事業有限公司。
    8. 法蘭西斯.福山 (民 91年)。後人類未來：基因工程的人性浩劫。時報文化出版公司。
    9. 法蘭西斯.西蒙 等 (民 94年)。打造全球生技品牌。天下遠見出版公司。
    10. 黃俊英、劉江彬 (民 87年)。智慧財產的法律與管理。華泰文化事業有限公司。
    11. 陳麗敏、羅淑慧 (民 93年)。生技製藥公司的策略聯盟佈局。生物技術開發中心。
    12. 陳宜中 (民 91年)。胚胎幹細胞研究的倫理爭議。354期，科學發展， p 4-11。
    13. 郭聰田 (民 94年)。企業永續經營三部曲 。282期，科技報導，p12-17。
    14. 馮震宇 (民 88年)。實用科技智財法全書。展智文化公司。
    15. 艾德蒙. 格雷 等 (民 88年)。管理學－競爭優勢。桂冠圖書公司。
    16. 楊秀儀 (民 94年)。論我國法上「告知後同意」法則之請求權基礎。「醫學倫理與法律」科技整合學術研討會/台大法律學院科際整合法律學研究所主辦。
    17. 蔡甫昌等 (民 91年)。醫學研究的倫理、法律與實務－臨床試驗受試者保護 研討會。台灣醫學會/台大醫學院主辦。
    18. 蔡甫昌、李明濱 (民 91年)。當代生命倫理學。醫學教育雜誌。
    19. 編輯群 (民 90年)。人體金礦最值錢？小心，有人盜用你的DNA。 BIOERA p 34-40。
    20. 編輯群 (民 94年)。台灣生技產業名錄 2004。生物技術開發中心。
    21. 編輯群 (民 89-94年)。生技醫藥速報半月刊 2000-2005。生物技術開發中心。
    22. 劉哲維、王維敏 (民 92年)。台灣製藥產業現況及發展趨勢。寶來證券研發專刊。
    23. 熊蕾 (民 91年)。新殖民主義掠奪備忘錄。http://southernmongolia.hypermart.net/forum/messages/41927.html。
    24. 顏厥安 (民 93年) 。 鼠肝與蟲臂之管制－法理學與生命倫理論文集。元照出版社。
    25. 蘿莉. 安德魯斯 等 (民 90年)。出賣愛因斯坦：人體組織販賣市場。時報文化出版社。
    英文資料：
    1. Check E. Ethics council calls for probe into assisted reproduction. 2004. Nature 428, p590.
    2. Crespi, R.S. Patenting and Ethics: a dubious connection. 2003. Pharmaliceensing. http://container. pharmaliceensing.com/features/disp.
    3. Demaine L. J. and Fellmeth A. X. Natural substances and patentable inventions. 2003. Science 300, p1375-1376.
    4. Dennis Carina. Synthetic sex cells. 2003. Nature 424, p364-366.
    5. Dhanda, R. K. 2003, Time for bioethics and business to start talking. Nature 421, p573.
    6. Editors. Antibody Therapeutics. D&MD report 2001.
    7. Editors. Therapeutic Proteins: strategic market analysis and forecasts to 2010. 2002. Datamonitor.
    8. Editors. The editors’ and reporters’ guide to Biotechnology. 2004-2005, Biotechnology Industry Organization.
    9. Editors. BioCentury (Daily news and weekly reports). 2000-2005. http://www.biocentury.com/flash/flash.cfm
    10. Editors. The World Market for Therapeutic Proteins 2005. 2005. Visiongain.
    11. Fairchild, A.L. and Bayer, R. Ethics and the conduct of public health surveillance. 2004. Science 303, p631-632.
    12. George, J. A. et al. Politics, morals and embryos.2004. Nature 431, p19-20.
    13. Hoffman, E. European Pharmecuticals. 2003. Bear Sterrns & Co. Inc.
    14. Karpowicz, Philip et al. It is ethical to transplant human stem cells into nonhuman embryos. 2004. Nature Medicine. 10, p331-335.
    15. Liu, R. M. et al. Psoriasis market outlook for 2003. 2003. Prudential Financial.
    16. Lo Bernard et al. Consent from donors for embryo and stem cell research. 2003. Science 301, p921.
    17. McLaren Anne. Ethical and social consideration of stem cell research. 2001. Nature 414, p129-131.
    18. Orive, G. et al. Controversies over stem cell research. 2003. Trends in Biotechnology. 21, 109-112.
    19. Powell Kendall. Seeds of doubt. 2003. Nature 422, p656-658.
    20. Rammensee, H. G. Protein surgery. 2004. Nature 427, p203-204.
    21. Rathmell, J. and Thompson, C. B. The central effectors of cell death in the immune system. 1999. Annu. Rev. Immunol. 17: 781-828.
    22. Sutton Gail. Are Biofirm courting the wrong investors? 2003. Genetic Engineering News 23, 9-57.
    23. Sulston J. and Ferry G. The common thread: a story of science, politics, ethics and the human genome. 2002. Joseph Henry Press.
    24. Walsh, Gary. Biopharmaceutical benchmarks-2003. 2003. Nature Biotechnology. 21, 865-870.
    25. Reichhardt, T. Studies of faith. 2004. Nature 432, p667-669.
    Description: 碩士
    國立政治大學
    科技管理研究所
    90359025
    93
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0090359025
    Data Type: thesis
    Appears in Collections:[Graduate Institute of Technology and Innovation Management] Theses

    Files in This Item:

    File Description SizeFormat
    35902501.pdf66KbAdobe PDF2974View/Open
    35902502.pdf86KbAdobe PDF2867View/Open
    35902503.pdf92KbAdobe PDF21181View/Open
    35902504.pdf80KbAdobe PDF21264View/Open
    35902505.pdf457KbAdobe PDF21547View/Open
    35902506.pdf545KbAdobe PDF24324View/Open
    35902507.pdf855KbAdobe PDF214964View/Open
    35902508.pdf558KbAdobe PDF24161View/Open
    35902509.pdf457KbAdobe PDF21379View/Open
    35902510.pdf90KbAdobe PDF21271View/Open
    35902511.pdf320KbAdobe PDF22468View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback